Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 7, 2013, Pages 1306-1316

  Kimura, Hiroaki ^a   Dobashi, Yoh ^b   Nojima, Takayuki ^c   Nakamura, Hiroyuki ^a   Yamamoto, Norio ^a   Tsuchiya, Hiroyuki ^a   Ikeda, Hiroko ^d   Sawada Kitamura, Seiko ^d   Oyama, Takeru ^a   Ooi, Akishi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

FISH; IHC; Liposarcoma; MDM2

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2; TUMOR MARKER;

ARTICLE; BIOPSY; CELL DIFFERENTIATION; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; FISH; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IHC; IMMUNOHISTOCHEMISTRY; LIPOMA; LIPOSARCOMA; MDM2; MYXOSARCOMA; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; UPREGULATION;

FISH; IHC; LIPOSARCOMA; MDM2;

BIOPSY; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOMA; LIPOSARCOMA; LIPOSARCOMA, MYXOID; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84882959591     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Nascimento AG. Dedifferentiated liposarcoma. Semin Diagn Pathol 2001 Nov; 18: 263-6
2. Tanas MR, Goldblum JR. Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol 2009 Nov; 16: 383-91.
3. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. Embo J 1991 Jun; 10: 1565-9.
4. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987 May; 13: 235-44.
5. Brown VD, Phillips RA, Gallie BL. Cumulative effect of phosphorylation of pRB on regulation of E2F activity. Mol Cell Biol 1999 May; 19: 3246-56.
6. Miura Y, Keira Y, Ogino J, Nakanishi K, Noguchi H, Inoue T, Hasegawa T. Detection of specific genetic abnormalities by fluorescence in situ hybridization in soft tissue tumors. Pathol Int 2012 Jan; 62: 16-27.
7. Downs-Kelly E, Goldblum JR, Patel RM, Weiss SW, Folpe AL, Mertens F, Hartke M, Tubbs RR, Skacel M. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms. Am J Surg Pathol 2008 Jan; 32: 8-13.
8. Weaver J, Downs-Kelly E, Goldblum JR, Turner S, Kulkarni S, Tubbs RR, Rubin BP, Skacel M. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol 2008 Aug; 21: 943-9.
9. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49: 223-41.
10. Binh MB, Garau XS, Guillou L, Aurias A, Coindre JM. Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. Am J Clin Pathol 2006 May; 125: 693-7.
11. Pilotti S, Della Torre G, Mezzelani A, Tamborini E, Azzarelli A, Sozzi G, Pierotti MA. The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. Br J Cancer 2000 Apr; 82: 1271-5.
12. Sirvent N, Coindre JM, Maire G, Hostein I, Keslair F, Guillou L, Ranchere-Vince D, Terrier P, Pedeutour F. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 2007 Oct; 31: 1476-89.
13. Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Kitamura SS, Ikeda H, Kawashima H, Dobashi Y. Gene amplification of ESR1 in breast cancers--fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. J Pathol 2012 May; 227: 8-16.
14. Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret Ad, Louis-Brennetot C, Aurias A, Coindre JM, Guillou L, Pedeutour F, Duval H, Collin C, de Pinieux G. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 2011 May; 24: 624-37.
15. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I, Coindre JM. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005 Oct; 29: 1340-7.
16. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. J Clin Pathol 2009 Dec; 62: 1127-35.
17. Weaver J, Rao P, Goldblum JR, Joyce MJ, Turner SL, Lazar AJ, López-Terada D, Tubbs RR, Rubin BP. Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma? Mod Pathol 2010 Oct; 23: 1301-6.
18. Shimada S, Ishizawa T, Ishizawa K, Matsumura T, Hasegawa T, Hirose T. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers. Hum Pathol 2006 Sep; 37: 1123-9.
19. Dumollard JM, Ranchere-Vince D, Burel F, Coindre JM, Tallini G, Ligon AH, Mayaud R, Turc-Carel C, Martin C, Mosnier JF, Pedeutour F. [Spindle cell lipoma and 13q deletion: diagnostic utility of cytogenetic analysis]. Ann Pathol 2001 Aug; 21: 303-10.
20. Weaver J, Goldblum JR, Turner S, Tubbs RR, Wang WL, Lazar AJ, Rubin BP. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol 2009 Jan; 22: 66-70.
21. Gisselsson D, Palsson E, Hoglund M, Domanski H, Mertens F, Pandis N, Sciot R, Dal Cin P, Bridge JA, Mandahl N. Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer 2002 Feb; 33: 133-40.
22. Mejia-Guerrero S, Quejada M, Gokgoz N, Gill M, Parkes RK, Wunder JS, Andrulis IL. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer 2010 Jun; 49: 518-25..
23. Coindre JM, Hostein I, Maire G, Derré J, Guillou L, Leroux A, Ghnassia JP, Collin F, Pedeutour F, Aurias A. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 2004 Jul; 203: 822-30.
24. McInnes C, Wang S, Anderson S, O'Boyle J, Jackson W, Kontopidis G, Meades C, Mezna M, Thomas M, Wood G, Lane DP, Fischer PM. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol 2004 Apr; 11: 525-34.
25. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004 Feb 6; 303: 844-8.
26. Muller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007 Jul 1; 121: 199-205.